


Journal Pre-proof

Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19

Alessandro D. Santin, MD, David E. Scheim, PhD, Peter A. McCullough, MD, MPH, Morimasa Yagisawa, PhD, Thomas J. Borody, MD, PhD, DSc



PII: S2052-2975(21)00088-3

DOI: <https://doi.org/10.1016/j.nmni.2021.100924>

Reference: NMNI 100924

To appear in: *New Microbes and New Infections*

Received Date: 10 May 2021

Revised Date: 21 June 2021

Accepted Date: 18 July 2021

Please cite this article as: Santin AD, Scheim DE, McCullough PA, Yagisawa M, Borody TJ, Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19, *New Microbes and New Infections*, <https://doi.org/10.1016/j.nmni.2021.100924>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 The Author(s). Published by Elsevier Ltd.

Mini-review and perspective

Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19

Alessandro D. Santin, MD¹

David E Scheim, PhD²

Peter A. McCullough,³ MD, MPH

Morimasa Yagisawa,⁴ PhD

Thomas J. Borody, MD, PhD, DSc⁵

¹ Professor, Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, USA

² Commissioned Officer, US Public Health Service, Inactive Reserve, Blacksburg, VA USA

³ Professor of Medicine, Texas A & M College of Medicine, Dallas, TX, USA

⁴ Visiting Professor, Ōmura Satoshi Memorial Institute, Infection Control Research Center, Kitasato University, Tokyo, Japan

⁵ Director, Centre for Digestive Diseases, New South Wales, Australia

Corresponding author:

David E. Scheim, PhD

Commissioned Officer, US Public Health Service, Inactive Reserve

2516 Ridge Road, Blacksburg, VA, USA

phone: 1 540 320-8013, fax 1 540 552-8014

dscheim@alum.mit.edu

Alternate corresponding author (for internal use, if DES is not immediately reachable):

Alessandro D. Santin MD, Yale University School of Medicine LSOG Bld. Room 312 375

Congress Avenue,

New Haven, CT 06520-8063

phone: 1 203-737-4450, fax: 1 203-737-4339

alessandro.santin@yale.edu

Mini-review and perspective

Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19

Alessandro D. Santin, MD¹

David E Scheim, PhD²

Peter A. McCullough,³ MD, MPH

Morimasa Yagisawa,⁴ PhD

Thomas J. Borody, MD, PhD, DSc⁵

¹ Professor, Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, USA

² Commissioned Officer, US Public Health Service, Inactive Reserve, Blacksburg, VA USA

³ Professor of Medicine, Texas A & M College of Medicine, Dallas, TX, USA

⁴ Visiting Professor, Ōmura Satoshi Memorial Institute, Infection Control Research Center, Kitasato University, Tokyo, Japan

⁵ Director, Centre for Digestive Diseases, New South Wales, Australia

Keywords. COVID-19, SARS-CoV-2, ivermectin, *H. pylori*

Abstract

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honored the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. The RCT using the highest IVM dose achieved a 92% reduction in mortality vs. controls (400 total subjects, $p < 0.001$). During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with extent of IVM distributions in all 25 states with $p < 0.002$. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Introduction

The 2015 Nobel prize for the discovery of ivermectin (IVM) and an antimalarial treatment was the Nobel committee's first award for treatment agents for infectious diseases since that of 1952 for streptomycin [1]. A macrocyclic lactone of multifaceted potency [2, 3], IVM as deployed worldwide since 1987 has made major inroads against two devastating tropical diseases, onchocerciasis and lymphatic filariasis [4]. During the year since IVM treatment of another global scourge, COVID-19, was first applied [5], results from more than 20 randomized clinical trials (RCTs) of IVM treatment of COVID-19 have been reported [2, 6, 7], with inpatient and outpatient treatments of COVID-19 conducted in 25 countries [2]. A likely biological mechanism has been indicated to be competitive binding with SARS-CoV-2 spike protein sites, as reviewed [8, 9].

Recently, Dr. Satoshi Omura, the Nobel co-laureate for the discovery of IVM, and colleagues conducted a comprehensive review of IVM clinical activity against COVID-19, concluding that the preponderance of the evidence demonstrated major reductions in mortality and morbidity [2]. Our review of that evidence, updated with consideration of several new studies, supports the same conclusion.

Animal studies for IVM treatment of SARS-CoV-2 and a closely related betacoronavirus

A framework for the examination of clinical IVM treatment results for COVID-19 is provided by related animal studies using IVM at low human-equivalent doses. In golden hamsters that were intranasally inoculated with SARS-CoV-2, causing symptomatic COVID-19 infections, concurrent dosing with IVM significantly reduced severity of clinical signs ($p < 0.001$). While viral load was not reduced, these improvements included one-third the incidence of anosmia and sharp reductions in the IL-6/IL-10 ratio in lung tissue [10]. In another animal model, mice were infected with mouse hepatitis virus MHV-A59 [11], a betacoronavirus strain that does not express hemagglutinin esterase [12], like SARS-CoV-2, SARS-CoV, and MERS [8]. Whereas infected mice had severe histopathological liver damage, IVM-treated mice had half the hepatic viral load and minimal liver damage not significantly different than that observed in uninfected controls.

RCTs for IVM treatment and prevention of COVID-19

More than 20 RCTs for IVM treatment of COVID-19 have been conducted to date, as cited above. A search of Google Scholar for meta-analyses of IVM treatment studies of COVID-19 that appeared in 2021 [13] yielded seven such studies that drew conclusions from RCTs only [6, 14-19]. The relative risk (RR) of mortality with IVM treatment vs. controls as calculated in four of these meta-analyses using Cochrane analysis methodology ranged from 0.25 to 0.37, with a mean of 0.31 [6, 14, 15, 19]. The three other meta-analyses reported odds ratios of 0.16, 0.21 and 0.33, with a mean of 0.23 [16-18]. Six of these seven meta-analyses concluded that there was a significant [6, 14-16] or possible [17, 18] indication of efficacy of IVM in reducing COVID-19 mortality. One found no evidence of IVM efficacy in its first version [20], reporting an RR of 1.11 for IVM treatment vs. controls, and stuck with that finding even after changing this RR value to 0.37 and correcting switched treatment and control deaths it had misreported for one study [21] in a revised version [19]. Among the most recent and comprehensive of these seven meta-analyses reported a pooled total of 31 deaths among 1,101 subjects in IVM treatment groups and 91 deaths among 1,064 controls from 11 RCTs, amounting to a 67% reduction in mortality, with a statistical significance for overall effect of $p=0.005$ [16]. The RCT that used the largest dose of IVM, 400 $\mu\text{g/kg}$ on each of days 1-4 [22], had 2 vs. 24 deaths in the treatment vs. control groups ($n=200$ each), a 92% reduction in COVID-19 mortality ($p<0.001$).

An objection that had been raised earlier in 2021 to the preponderance of clinical evidence for efficacy of IVM treatment of COVID-19 as summarized above was that none of these RCTs had been published in mainstream peer-reviewed scientific journals [23]. Closing that gap, however, was the publication in 2021 in journals from major scientific publishers of five such RCTs for COVID-19 treatment [24-28], each showing multiple clinical benefits for IVM vs. controls, most of these to statistical significance at $p<0.002$. Also published in 2021 were three other RCTs for IVM treatment of COVID-19: one that reported briefer hospital stays for IVM treatment short of statistical significance ($p=0.08$) [29], another that compared IVM with two other drug treatment groups but not a placebo group and found no benefit

66 [30], and an additional study conducted in Cali, Columbia with mix-ups between treatment and placebo
67 doses as described below.

68 Another objection that has been raised to the RCT evidence supporting IVM efficacy was that study
69 populations were too small [31]. Yet it is well known in clinical trial design that highly effective drugs
70 will establish statistically significant results with smaller sample sizes, with larger study populations
71 required for minimally effective drugs [32]. For example, as noted above, the highest dose IVM treatment
72 study for COVID-19 that tracked mortality had 2 vs. 24 deaths in treatment vs. control arms of 200
73 subjects each [22], with a z test p-value of 0.0006 [33]. But for a drug with a more modest RR of 75%, for
74 example, the treatment and control arms would need more than 3,800 subjects each to yield the same
75 statistical significance [33]. Although large study populations are useful to screen for adverse effects
76 (AEs) of new drugs, IVM has been used safely in 3.7 billion doses worldwide since 1987 [2, 3] and is
77 well tolerated even at much greater than the standard single dose of 200 µg/kg [34, 35]. It has been used
78 in RCTs for COVID-19 treatment at cumulative doses of 1,500 µg/kg [36], 1,600 µg/kg [22] and 3,000
79 µg/kg[37] over 4 or 5 days with only small percentages of mild or transient adverse effects.

80 Among these RCTs that established safety for high-dose IVM treatment of COVID-19 was one conducted
81 in Cali, Columbia with generally mild COVID-19 cases, median age 37, having only one death in the
82 control group [36]. The study found no statistically significant symptom improvements with IVM
83 treatment, yet reported a striking anomaly: AEs distinctive for its high IVM dose, described in the study
84 protocol as “security parameters” for its IVM use, occurred at almost identical rates in its IVM and
85 placebo arms. These included transient incidences of blurred vision (11.3%, 11.6%) and dizziness
86 (35.6%, 34.3%). These indications of IVM use in controls occurred as over-the-counter sales of IVM
87 surged in the study region during the study period (Supplementary Table 1). Further questions as to the
88 study’s treatment/control boundaries were raised by the mistaken substitution of IVM for placebo for 38
89 patients, discovered by the lead pharmacist a month after the fact (study, p. 3; study protocol supplement,
90 p. 43). In addition, blinding was breached by the use of dextrose-saline solution as the placebo for 64

control patients (IVM tastes distinctively bitter), while the composition of the replacement placebo solution was not specified [38].

Supporting the findings of IVM efficacy in COVID-19 treatment as summarized above were indications of activity against SARS-CoV-2 in prevention studies. Three RCTs evaluated the prophylactic effect of IVM administered to cohorts of 100 [22], 117 [39] and 203 [40] subjects exposed to COVID-19 patients. These studies, all using IVM in doses of at least 150 µg/kg per week, reported statistically significant reductions in COVID-19 incidences, with respective RRs of 20%, 26% and 13% as compared with controls, and greater reductions in incidences of moderate and severe cases. Another RCT for COVID-19 prevention administered just one dose of IVM at 12 mg (about 150 µg/kg) to 617 subjects on day one of a 42-day observation period, while three other preventative regimens were each administered daily over that period [41]. IVM at that single low dose yielded the best results of these four regimens, with highly statistically significant reductions of close to 50% in both symptomatic COVID-19 and acute respiratory symptoms vs. controls.

14-fold reductions in excess deaths with IVM use in Peru, then 13-fold increase after IVM restricted

The clinical experience of IVM treatments of COVID-19 in 25 countries extends far beyond the RCT results summarized, yet incomplete tracking and lack of control data exclude most of this for evaluation. The record of nationally authorized such treatments in Peru provides a notable exception [42]. In ten states of Peru, mass IVM treatments of COVID-19 were conducted through a broadside, army-led effort, *Mega-Operación Tayta (MOT)*, that began on different dates in each state. In these *MOT* states, excess deaths dropped sharply over 30 days from peak deaths by a mean of 74%, in close time conjunction with *MOT* start date (Figure 1B). In 14 states of Peru having locally administered IVM distributions, the mean reduction in excess deaths over 30 days from peak deaths was 53%, while in Lima, which had minimal IVM distributions during the first wave of the pandemic due to restrictive government policies there, the corresponding 30-day decrease in excess deaths was 25%.

116 Reductions in excess deaths by state (absolute values) correlated with extent of IVM distribution
117 (maximal-*MOT* states, moderate-local distributions, and minimal-Lima) with Kendall $\tau_b = 0.524$,
118 $p < 0.002$, as shown in Figure 1C. Nationwide, excess deaths decreased 14-fold over four months through
119 December 1, 2020. After a restrictive IVM treatment policy was enacted under a new Peruvian president
120 who took office on November 17, however, deaths increased 13-fold over the two months following
121 December 1, through February 1, 2021 (Figure 1A). Potential confounding factors, including lockdowns
122 and herd immunity, were ruled out using Google community mobility data, seropositivity rates,
123 population densities and geographic distributions of SARS-CoV-2 genetic variations and by restricting all
124 analysis except that for Figure 1A to ages ≥ 60 . Excess deaths was used in all analyses rather than
125 COVID-19 case fatalities as gross underreporting of pandemic deaths by case fatalities was known to the
126 Peruvian ministry of health since July 2020 [43]. This disparity has been consistently manifested in the
127 national health database figures for COVID-19 case fatalities vs. all natural-cause deaths since that date
128 [42].




Figure 1. A) Excess all-cause deaths (all ages), national population of Peru. These decreased 14-fold August 1 through December 1, 2020; then, after IVM use was restricted, increased 13-fold through February 1. For A and B, y values are 7-day moving averages; for B and C, ages ≥ 60 . Data are from Peru's National Death Information System (SINADEF). B) Drops in excess deaths for all states of operation *MOT*, an army-led program of mass IVM distributions, but Pasco, which had them on 3 dates. • *MOT* start date; ▲ peak deaths; ■ day of peak deaths + 30 days. Junin distributed IVM through local channels 13 days before *MOT* start. C) Reductions in excess deaths at +30 days after peak deaths for the 25 states by extent of IVM distributions: maximal-*MOT* (+), mean -74%; moderate-local distributions (○), mean -53%; and minimal-Lima (x), -25%. The absolute value of these reductions by state correlated with extent of IVM distributions with Kendall $\tau_b = 0.524$, $p < 0.002$ (Spearman $\rho = 0.619$, $p < 0.001$). All these data are from publicly accessible Peruvian national databases, with associated frozen datasets available from the Dryad data repository [42].

IVM-based combination treatments and other research in progress

Combination treatments using IVM and adjuncts have shown indications of efficacy against COVID-19 in RCTs conducted to date [24, 44]. Results using IVM, doxycycline and zinc to treat serious and critical cases having $\text{spO}_2 \leq 90$ prior to treatment, with spO_2 changes tracked 24 hours after treatment, will be reported by TJB with Sabine Hazan, MD. Pronounced improvements of serious COVID-19 symptoms within 1-2 days after IVM administration have been observed in several patients treated by the lead author (ADS), and studies to objectively track such short-term clinical benefits of IVM for COVID-19 are underway. Information on other combination treatments using IVM with agents such as fluvoxamine, for which clinical studies also indicate significant benefits [45], is provided by the USA-based FLCCC alliance (<https://covid19criticalcare.com>).

The curative potential of combination therapy was demonstrated in a medical breakthrough of three decades prior for another disease, peptic ulcers, for which the discovery of its underlying bacterial cause, *Helicobacter pylori*, was honored with the Nobel Prize for Medicine, in 2005. In 1990, Dr. Thomas J. Borody published the original clinical trial of a combination treatment for *H. pylori*, achieving a 96% cure rate for a triple therapy consisting of three repurposed drugs, bismuth subcitrate and two antibiotics [46]. Between 1990 and 2015, an estimated 18,665 deaths were prevented by the timely application of this triple therapy for peptic ulcer disease in Australia [47]. After expiration of the patents for two palliative drugs for this condition, Tagamet and Zantac [48], which had each earned billions of dollars, triple therapy became the standard of care for peptic ulcers in the rest of the world by the late 1990s.

Conclusion

We believe that the evidence to date supports the worldwide extension of IVM treatments for COVID-19, complementary to immunizations. The indicated biological mechanism of IVM,

competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, as reviewed [8], possibly yielding full efficacy against emerging viral mutant strains. IVM has been safely used in 3.7 billion doses since 1987, well tolerated even at much greater than standard doses [34, 35] and used without serious AEs in the three high-dose COVID-19 treatment studies noted above [34, 36, 37]. In the current international emergency of COVID-19, with mutant viral strains, vaccination refusals and potentially waning immunities over months presenting new challenges, IVM can be an effective component of the mix of therapeutics deployed against this pandemic.

Funding

No funding was received for this perspective.

Ethical approval and consent to participate

This is a review and ethical approval was not required.

Conflict of interest. TJB is a principal in Topelia Therapeutics (Ventura, California), which seeks to commercialize cost-effective treatments for COVID-19, including IVM. All other authors report no conflicts of interest.

References

1. Ergonul O, Yalcin CE, Erkent MA, Demirci M, Uysal SP, Ay NZ, et al. Who can get the next Nobel Prize in infectious diseases? *International Journal of Infectious Diseases*. 2016;45:88-91.
2. Yagisawa M, Foster PJ, Hanaki H, Omura S. Global Trends in Clinical Studies of Ivermectin in COVID-19. *The Japanese Journal of Antibiotics*. 2021;74(1).
3. Campbell WC. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. *Curr Pharm Biotechnol*. 2012;13(6):853-865.
4. Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. *Proc Jpn Acad Ser B Phys Biol Sci*. 2011;87(2):13-28.
5. Rajter JC, Sherman MS, Fattah N, Vogel F, Sacks J, Rajter J-J. Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study). *CHEST*. 2020. doi:10.1016/j.chest.2020.10.009.
6. Hill A, Abdulmir A, Ahmed S, Asghar A, Babalola OE, Basri R, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. *Research Square*. 2021. doi:10.21203/rs.3.rs-148845/v1.
7. Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. *American Journal of Therapeutics*. 2021;28(3):e299-e318.
8. Scheim DE. From cold to killer: How SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature SSRN. 2020 [Available from: <http://ssrn.com/abstract=3706347>]. Access date March 30, 2021.
9. Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. *The Journal of Antibiotics*. 2021. 10.1038/s41429-021-00430-5.
10. Melo GD, Lazarini F, Larrous F, Feige L, Kergoat L, Marchio A, et al. Anti-COVID-19 efficacy of ivermectin in the golden hamster. *bioRxiv*. 2020. doi:10.1101/2020.11.21.392639.
11. Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, et al. Ivermectin reduces *in vivo* coronavirus infection in a mouse experimental model. *Scientific Reports*. 2021;11(1):7132.
12. Kazi L, Lissenberg A, Watson R, de Groot RJ, Weiss SR. Expression of Hemagglutinin Esterase Protein from Recombinant Mouse Hepatitis Virus Enhances Neurovirulence. *J Virol*. 2005;79(24):15064-15073.
13. Search for papers having "ivermectin," "meta," and "COVID" OR "SARS" in the title, appearing in 2021. [Available from: https://scholar.google.com/scholar?as_q=ivermectin+meta+%28COVID+OR+SARS%29&as_epq=&as_oq=&as_eq=&as_occt=title&as_sauthors=&as_publication=&as_ylo=2021&as_yhi=2021&hl=en&as_sdt=0%2C47]. Access date June 13, 2021.
14. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. *American Journal of Therapeutics*. 2021. doi:10.1097/MJT.0000000000001402.

- 221 15. Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from
222 Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies.
223 *Reviews in Medical Virology*. 2021. <https://doi.org/10.1002/rmv.2265>:e2265.
- 224 16. Karale S, Bansal V, Makadia J, Tayyeb M, Khan H, Ghanta SS, et al. A Meta-analysis of Mortality,
225 Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in
226 COVID-19 Patients. *medRxiv*. 2021. doi:10.1101/2021.04.30.21256415.
- 227 17. Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of ivermectin and
228 mortality in patients with COVID-19: a meta-analysis. *Pharmacological Reports*. 2021.
229 10.1007/s43440-021-00245-z.
- 230 18. Rodríguez-Gutiérrez R, Raygoza-Cortez K, Garcia-Leal M, Sáenz-Flores M, Solis RC, Flores-
231 Rodríguez A, et al. Ivermectin in the Prophylaxis and Treatment of Patients with SARS-CoV-2: A
232 Living Systematic Review and Meta-Analysis SSRN 2021 [Available from:
233 <http://ssrn.com/abstract=3802499>]. Access date June 13, 2021.
- 234 19. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the
235 treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.
236 *medRxiv*. 2021. doi:10.1101/2021.05.21.21257595.
- 237 20. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the
238 treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
239 (version 1). *medRxiv*. 2021. doi:10.1101/2021.05.21.21257595v1.
- 240 21. Niaee MS, Gheibi H, Namdar P, Allami A. Ivermectin as an adjunct treatment for hospitalized adult
241 COVID-19 patients; A randomized multi-center clinical trial. *Research Square*. 2020.
242 doi:10.21203/rs.3.rs-109670/v1.
- 243 22. Elgazzar A, Hany B, Abo Youssef S, Hany B. Efficacy and Safety of Ivermectin for Treatment and
244 prophylaxis of COVID-19 Pandemic. *Research Square*. 2020. doi:10.21203/rs.3.rs-100956/v1.
- 245 23. Sax PE. Ivermectin for COVID-19 — Breakthrough Treatment or Hydroxychloroquine Redux? :
246 *NEJM Journal Watch*; January 4, 2021 [Available from: [https://blogs.jwatch.org/hiv-id-](https://blogs.jwatch.org/hiv-id-observations/index.php/ivermectin-for-covid-19-breakthrough-treatment-or-hydroxychloroquine-redux/2021/01/04/)
247 [observations/index.php/ivermectin-for-covid-19-breakthrough-treatment-or-hydroxychloroquine-](https://blogs.jwatch.org/hiv-id-observations/index.php/ivermectin-for-covid-19-breakthrough-treatment-or-hydroxychloroquine-redux/2021/01/04/)
248 [redux/2021/01/04/](https://blogs.jwatch.org/hiv-id-observations/index.php/ivermectin-for-covid-19-breakthrough-treatment-or-hydroxychloroquine-redux/2021/01/04/)]. Access date June 13, 2021.
- 249 24. Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir AKMH, Sayeed SKJB, et al. Ivermectin in
250 combination with doxycycline for treating COVID-19 symptoms: a randomized trial. *Journal of*
251 *International Medical Research*. 2021;49(5):03000605211013550.
- 252 25. Okumuş N, Demirtürk N, Çetinkaya RA, Güner R, Avcı İY, Orhan S, et al. Evaluation of the
253 effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. *BMC*
254 *Infectious Diseases*. 2021;21(1):411.
- 255 26. Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, et al. Effects of a Single Dose of
256 Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot
257 Clinical Trial in Lebanon. *Viruses*. 2021;13(6):989.
- 258 27. Shahbaznejad L, Davoudi A, Eslami G, Markowitz JS, Navaeifar MR, Hosseinzadeh F, et al. Effect of
259 ivermectin on COVID-19: A multicenter double-blind randomized controlled clinical trial. *Clinical*
260 *Therapeutics*. 2021. <https://doi.org/10.1016/j.clinthera.2021.04.007>.
- 261 28. Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, et al.
262 The effect of early treatment with ivermectin on viral load, symptoms and humoral response in

- patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. *EClinicalMedicine*. 2021. 10.1016/j.eclinm.2020.100720.
29. Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, et al. Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study. *Journal of Medical Virology*. 2021. <https://doi.org/10.1002/jmv.27122>.
 30. Galan LEB, Santos NMD, Asato MS, Araújo JV, de Lima Moreira A, Araújo AMM, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. *Pathog Glob Health*. 2021;115(4):235-242.
 31. COVID-19 Scientific Advisory Group Rapid Evidence Report: Ivermectin in the Treatment and Prevention of COVID-19: Alberta Health Services; February 2, 2021 [Available from: <https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-ivermectin-in-treatment-and-prevention-rapid-review.pdf>]. Access date June 13, 2021.
 32. Sakpal TV. Sample size estimation in clinical trial. *Perspect Clin Res*. 2010;1(2):67-69.
 33. Kohn M, Senyak J. Sample Size Calculators: UCSF CTSI; [updated April 29, 2021. Available from: <https://www.sample-size.net/>]. Access date June 15, 2021.
 34. Navarro M, Camprubí D, Requena-Méndez A, Buonfrate D, Giorli G, Kamgno J, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*. 2020;75(4):827-834.
 35. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. *J Clin Pharmacol*. 2002;42(10):1122-1133.
 36. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *JAMA*. 2021. 10.1001/jama.2021.3071.
 37. Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial: SSRN; 2020 [Available from: <http://ssrn.com/abstract=3714649>]. Access date June 10, 2021.
 38. Scheim DE, Hibberd JA, Chamie JJ. Protocol violations in López-Medina et al.: 38 switched ivermectin (IVM) and placebo doses, failure of blinding, ubiquitous IVM use OTC in Cali, and nearly identical AEs for the IVM and control groups: OSF Preprints; 2021 [Available from: <https://doi.org/10.31219/osf.io/u7ewz>]. Access date June 10, 2021.
 39. Chahla RE, Medina Ruiz L, Ortega ES, Morales MF, Barreiro F, George A, et al. A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents. *medRxiv*. 2021. doi:10.1101/2021.03.26.21254398.
 40. Shouman W, Hegazy A, Nafae R, Ragab M, Samra S, Ibrahim D, et al. Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19 (NCT number: 04422561). *Journal of Clinical and Diagnostic Research*. 2021;15(2):OC27.
 41. Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. *International Journal of Infectious Diseases*. 2021;106:314-322.

- 304 42. Chamie JJ, Hibberd JA, Scheim DE. Ivermectin for COVID-19 in Peru: 14-fold reduction in
 305 nationwide excess deaths, $p < 0.002$ for effect by state, then 13-fold increase after ivermectin use
 306 restricted: OSF Preprints; 2021 [Available from: <https://doi.org/10.31219/osf.io/9egh4>]. Access
 307 date June 10, 2021. Associated frozen data from the Peruvian SINADEF database used in this
 308 analysis is available from the Dryad data repository at <https://doi.org/10.5061/dryad.dv41ns1xr>.
- 309 43. Covid-19: segundo informe para actualizar cifra de fallecidos se conocerá esta semana. Andina.
 310 Agencia Peruana de Noticias. 2020 2020/07/26.
- 311 44. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulmir AS. Controlled randomized
 312 clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.
 313 medRxiv. 2020. doi:10.1101/2020.10.26.20219345.
- 314 45. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of Its Mechanism
 315 of Action and Its Role in COVID-19. *Frontiers in Pharmacology*. 2021;12(763).
- 316 46. George LL, Borody TJ, Andrews P, Devine M, Moore-Jones D, Walton M, et al. Cure of duodenal
 317 ulcer after eradication of *Helicobacter pylori*. *Med J Aust*. 1990;153(3):145-149.
- 318 47. Eslick GD, Tilden D, Arora N, Torres M, Clancy RL. Clinical and economic impact of "triple therapy"
 319 for *Helicobacter pylori* eradication on peptic ulcer disease in Australia. *Helicobacter*.
 320 2020;25(6):e12751.
- 321 48. Berndt ER, Kyle M, Ling D. The Long Shadow of Patent Expiration: Generic Entry and Rx-to-OTC
 322 Switches. In: Feenstra RC, Shapiro MD, editors. *Scanner Data and Price Indexes*. Chicago:
 323 Univeristy of Chicago Press; 2003. p. 229-274.

324